Patient info Open main menu

Nitisinone 5 mg hard capsules – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
5 mg
Contains active substance:
ATC code:

Patient leaflet - Nitisinone 5 mg hard capsules

1. What Nitisinone is and what it is used for

Nitisinone contains the active substance

nitisinone. Nitisinone is used to treat:

  • a rare disease called hereditary tyrosinemia

    type 1 in adults, adolescents and children (in any age range)

  • a rare disease called alkaptonuria (AKU) in

    adults.

In these diseases your body is unable to

completely break down the amino acid

tyrosine (amino acids are building blocks of

our proteins), forming harmful substances.

These substances are accumulated in your

body. Nitisinone blocks the breakdown of

tyrosine and the harmful substances are not

formed.

For the treatment of hereditary tyrosinemia

type 1, you must follow a special diet while

you are taking this medicine, because

tyrosine will remain in your body. This special

diet is based on low tyrosine and

phenylalanine (another amino acid) content.

For the treatment of AKU, your doctor may

advise you to follow a special diet.

2. What you need to know before you take Nitisinone

Do not take Nitisinone

  • if you are allergic to nitisinone or any of the

    other ingredients of this medicine (listed in

    section 6).

Do not breast-feed while taking this medicine, see section “Pregnancy and breast-feeding”.

Warnings and precautions

Talk to your doctor or pharmacist before

taking Nitisinone.

ophthalmologist before and regularly during

nitisinone treatment. If you get red eyes or

any other signs of effects on the eyes, contact your doctor immediately for an eye

examination. Eye problems could be a sign of inadequate dietary control (see section 4).

During the treatment, blood samples will be drawn in order for your doctor to check whether the treatment is adequate and to make sure that there are no possible side effects causing blood disorders.

If you receive Nitisinone for treatment of hereditary tyrosinemia type 1, your liver will be checked at regular intervals because the disease affects the liver.

Follow-up by your doctor should be performed every 6 months. If you experience any side effects, shorter intervals are recommended.

Other medicines and Nitisinone

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Nitisinone may interfere with the effect of other medicines, such as:

  • Medicines for epilepsy (such as phenytoin)
  • Medicines against blood clotting (such as warfarin)

Nitisinone with food

If you start treatment by taking it with food, it is recommended that you carry on taking it with food throughout your course of treatment.

Pregnancy and breast-feeding

The safety of this medicine has not been studied in pregnant and breast-feeding women. Please contact your doctor if you plan to become pregnant. If you become pregnant you should contact your doctor immediately. Do not breast-feed while taking this medicine, see section “Do not take Nitisinone”.

Driving and using machines

This medicine has minor influence on the ability to drive and use machines. However, if you experience side effects affecting your vision you should not drive or use machines until your vision is back to normal (see section 4 “Possible side effects”).

3. How to take Nitisinone

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

For hereditary tyrosinemia type 1, treatment with this medicine should be started and supervised by a doctor experienced in the treatment of the disease.

For hereditary tyrosinemia type 1, the recommended total daily dose is 1 mg/kg body weight administered orally. Your doctor will adjust the dose individually.

Package leaflet: Information for the user

Nitisinone

Nitisinone 2 mg hard capsules Nitisinone 5 mg hard capsules Nitisinone 10 mg hard capsules Nitisinone 20 mg hard capsules nitisinone

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

    03020060P2001.04

It is recommended to administer the dose once daily.

However, due to the limited data in patients with body weight <20 kg, it is recommended to divide the total daily dose into two daily administrations in this patient population.

For AKU, the recommended dose is 10 mg once daily.

If you have problems with swallowing the capsules, you may open the capsule and mix the powder with a small amount of water, apple juice, soft food, such as apple sauce, or formula diet, including amino acid infant formula, just before you take it.

If you take more Nitisinone than you should

If you have taken more of this medicine than you should, contact your doctor or pharmacist as soon as possible.

If you forget to take Nitisinone

Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, contact your doctor or pharmacist.

If you stop taking Nitisinone

If you have the impression that the medicine is not working properly, talk to your doctor. Do not change the dose or stop the treatment without talking to your doctor.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you notice any side effects relating to the eyes, talk to your doctor immediately to have an eye examination. Treatment with nitisinone leads to higher levels of tyrosine in the blood which can cause eye related symptoms. In patients with hereditary tyrosinemia type 1, commonly reported eye related side effects (may affect more than 1 in 100 people) caused by higher tyrosine levels are inflammation in the eye (conjunctivitis), opacity and inflammation in the cornea (keratitis), sensitivity to light (photophobia) and eye pain. Inflammation of the eyelid (blepharitis) is an uncommon side effect (may affect up to 1 in 100 people).

In AKU patients, eye irritation (keratopathy) and eye pain are very commonly reported side effects (may affect more than 1 in 10 people).

Other side effects reported in patients with hereditary tyrosinemia type 1 are listed below:

Other common side effects

  • Reduced number of platelets

    (thrombocytopenia) and white blood cells (leukopenia), shortage of certain white blood cells (granulocytopenia).

Other uncommon side effects

  • increased number of white blood cells (leucocytosis),
  • itching (pruritus), skin inflammation (exfoliative dermatitis), rash.

Other side effects reported in patients with AKU are listed below:

Other common side effects

  • bronchitis
  • pneumonia
  • itching (pruritus), rash

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website:

    www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Nitisinone

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the bottle, the blister and the carton after “EXP”. The expiry date refers to the last day of that month.

Store below 30°C.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Nitisinone contains

  • The active substance is nitisinone Nitisinone 2 mg. Each hard capsule contains 2 mg nitisinone

    Nitisinone 5 mg. Each hard capsule contains 5 mg nitisinone

    Nitisinone 10 mg. Each hard capsule contains 10 mg nitisinone

    Nitisinone 20 mg. Each hard capsule contains 20 mg nitisinone

  • The other ingredients are:

    Hard capsule content

    Starch, pregelatinised

    Stearic acid

    Capsule shell

    Gelatin

    Titanium dioxide (E 171)

    Printing ink

    Shellac

    Propylene glycol

    Indigotine aluminum lake (E 132)

What Nitisinone looks like and contents of the pack

The hard capsules are white, opaque, imprinted with the strength “2” or “5” or “10” or “20” and the “company logo”, in dark blue. The capsule contains a white to off-white powder.

Nitisinone is available in plastic bottles with child-proof closures of 60 capsules, and OPA/Alu/PVC - Alu perforated unit dose blisters of 60 capsules.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

LogixX Pharma Ltd

Merlin House, Brunel Road,

Theale, Reading,

RG7 4AB

UK

Manufacturer

Doppel Farmaceutici S.r.l.

Via Volturno 48

20089 Quinto de’ Stampi - Rozzano (MI), Italy

This leaflet was last revised in 11/2024

Detailed information on this medicine is available on the website of MHRA Website: http://www.mhra.gov.uk.

CustomerDipharma SA
Product NameNitisinone combi - PIL
MarketUK
Language/sEnglish
03020060P2001.04
Manufacturer CodeN/A
PD Ref.Nitisinone_UK_2mg-5mg-10m-20mg_PIL_ver01— (** to follow final proof)
Customer Ref.N/A
Issue01
Date07 November 2024
SPECIFICATION DETAILS
Origination07 November 2024 — (as Issue 01)
155 x 308 mm
Border10 mm
N/A
Font detailsMain title: Arial - Bold — 30 pt Titles: Arial - Bold — 11 pt Sub-titles: Arial - Bold — 9 pt Body copy: Arial - Regular — 9 pt
Black - K

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 36959/0009

Last revision stated in the text: November 2024 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Nitisinone 5 mg hard capsules

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Nitisinone
Strength 5 mg
Pharmaceutical form Oral capsule
White, opaque capsules (shell size 3, length 15.9 mm) imprinted “company logo” on the cap and “5” on the body of the capsule in dark blue ink.
The capsules contain a white to off white powder.
How is it taken Oral
Excipients Starch, pregelatinised, Stearic acid, Gelatin, Titanium dioxide (E 171), Shellac, Propylene glycol, Indigotine alluminium lake (E 132)
Pack sizes 60 capsule
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years.
Storage Store below 30°C.
Drug group (ATC) Other alimentary tract and metabolism products, Various alimentary tract and metabolism products
  1. A Alimentary tract and metabolism drugs
    1. A16 Other alimentary tract and metabolism products
      1. A16A Other alimentary tract and metabolism products
        1. A16AX Various alimentary tract and metabolism products
          1. A16AX04 nitisinone
Marketing authorisation PL 36959/0009 (first authorised 7 September 2022)
Marketing authorisation holder LogixX Pharma Ltd
Codes GTIN 5060347610039 · BNF 09080100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.